IL5 and eosinophilic granulomatosis with polyangiitis: In our one-year monocentric observational study, we analyzed the immunological and clinical profiles of 20 EGPA pts with a particular focus on cutaneous manifestations, and response to biologic therapy, specifically anti-IL-5 treatment with Mepolizumab.